OmegAD (Omega-3 and Alzheimer's Disease)

Karolinska University Hospital204 enrolled

Overview

Memory loss and difficulties with thinking associated with Alzheimer's disease (AD) may be due to a deficiency in the brain of a fatty acid named DHA. The aim of this trial is to see if dietary supplementation with a preparation, rich in DHA, will halt cognitive impairment in AD patients

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

204

Conditions

Alzheimer's Disease

Interventions

EPAX 1050TGDRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: Alzheimer's disease with MMSE 15-30, living in own homes, treated with stable dose of acetylcholine esterase inhibitor for \>3 months and remaining on that treatment for the study period Exclusion Criteria: Already treated with omega-3 fatty acids, NSAIDs, warfarin, being an alcohol abuser, suffering from serious concomitant disease or not having a caregiver

Locations (1)

Karolinska University Hospital Huddinge

Stockholm, Sweden

Outcomes

Primary Outcomes

Cognition measured according to ADAS-cog, MMSE scales

Secondary Outcomes

Safety, tolerability, blood pressure

Gene expression

mRNA expression and DNA methylation changes in blood leukocytes in relation to changes of plasma and cerebrospinal concentrations of omega-3 fatty acids

Time frame: 2007-2018

Dose-response studies in relation to APOE4 status, to body weight and to gender

Analysis of changes of plasma and cerebrospinal fluid concentrations of omega-3 fatty acids in relation to APOE4 status, body weight and gender, as well as to changes in ADAS-cog and MMSE as measures of cognition.

Time frame: 2007-2018

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.